Imaging brain cholinergic activity with positron emission tomography: Its role in the evaluation of cholinergic treatments in Alzheimer's dementia

Biological Psychiatry

Volumn 49, Issue 3, 2001, Pages 211-220

  Volkow, Nora D ^a,b   Ding, Yu Shin ^a   Fowler, Joanna S ^a   Gatley, Samuel J ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Amyloid; Cholinesterase; FDG; Muscarinic receptors; Nicotinic receptors

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; AMYLOID; AZETIDINE DERIVATIVE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; EPIBATIDINE; MUSCARINIC RECEPTOR; NICOTINE; NICOTINIC RECEPTOR; PHYSOSTIGMINE; TACRINE; TRACER; VELNACRINE; VESICULAR ACETYLCHOLINE TRANSPORTER;

ALZHEIMER DISEASE; BEHAVIOR; BRAIN BLOOD FLOW; BRAIN FUNCTION; CELL VIABILITY; CHOLINERGIC ACTIVITY; COGNITION; DIAGNOSTIC VALUE; DRUG ACTIVITY; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RECEPTOR BINDING; GLUCOSE METABOLISM; HUMAN; IMAGING; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENILE PLAQUE;

ACETYLCHOLINE; ALZHEIMER DISEASE; BRAIN; CHOLINERGIC AGENTS; HUMANS; RECEPTORS, NICOTINIC; TOMOGRAPHY, EMISSION-COMPUTED; TREATMENT OUTCOME;

EID: 0035251813     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(00)01112-4     Document Type: Review

References (70)

1. PET imaging of tangles and plaques in Alzheimer disease with a highly hydrophobic probe
2. Neurochemical correlates of dementia severity in Alzheimer's disease: Relative importance of the cholinergic deficits
3. 123I-labelled serum amyloid P component and SPECT
4. 11C]methoxy-3-[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]-1,2- benzisoxazole as an in vivo radioligand for acetylcholinesterase
5. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects
6. 18F]FP-TZTP: Control and competition studies
7. 18F]F-A-85380: A PET radioligand for alpha4beta2 nicotinic acetylcholine receptors
8. A comparison of the binding of nicotine and nornicotine stereoisomers to nicotinic binding sites in rat brain cortex
9. Alzheimer's disease: A disorder of cortical cholinergic innervation
10. SPECT functional brain imaging. Technical considerations
11. 11C-raclopride is altered by drugs that modify synaptic dopamine levels
12. Age-related decreases in muscarinic cholinergic receptor binding in the human brain measured with positron emission tomography (PET)
13. Mapping nicotinic acetylcholine receptors with PET
14. 18F]fluoro-3-(2(S)-azetidinylmethoxy) pyridine for PET studies of nicotinic acetylcholine receptors
15. 18F]N-methyl-NFEP: Kinetics, nicotine effect and toxicity
16. Occupancy of brain nicotinic acetylcholine receptors by nicotine doses equivalent to those obtained when smoking a cigarette
17. External imaging of cerebral muscarinic acetylcholine receptors
18. 18F-2-Deoxy-2-fluoro-D-glucose as a tracer in the positron emission tomographic study of senile dementia
19. Diagnosis of early Alzheimer's disease
20. Cholinergic stimulation alters performance and task-specific regional cerebral blood flow during working memory
21. Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer disease
22. Intravenous physostigmine treatment of Alzheimer's disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG
23. 11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET
24. 11C-nicotine to positron emission tomography: R-isomer for cerebral blood flow and s-isomer for study of Alzheimer's disease
25. Impairment of neocortical metabolism predicts progression in Alzheimer's disease
26. The scintigraphic appearance of Alzheimer's disease: A prospective study using technetium-99 m-HMPAO SPECT
27. 11C]A-84543: An enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors
28. In vivo mapping of cholinergic neurons in the human brain using SPECT and IBVM
29. In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease
30. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease
31. Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates
32. Nicotine enhances the biosynthesis and secretion of transthyretin from the choroid plexus in rats: Implications for beta-amyloid formation
33. 11C]Nicotine binding assessed by PET: A dual tracer model evaluated in the rhesus monkey brain
34. 18F](+)-4-fluorobenzyltrozamicol: In vitro binding studies and positron emission tomography studies in nonhuman primates
35. Reduced antinociception in mice lacking neuronal nicotinic receptor subunits
36. Overlap between acetylcholinesterase-rich and choline acetyltransferase-positive (cholinergic) axons in human cerebral cortex
37. Nicotine, brain nicotinic receptors, and neuropsychiatric disorders
38. Fluoro-norchloroepibatidine: Preclinical assessment of acute toxicity
39. 18F]Fluoroethoxy-benzovesamicol, a PET radiotracer for the vesicular acetylcholine transporter and cholinergic synapses
40. PET quantification of specific binding of carbon-11-nicotine in human brain
41. PET studies and cholinergic therapy in Alzheimer's disease
42. Long-term tacrine treatment in three mild Alzheimer patients: Effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities
43. Nicotine receptors in the brain of patients with Alzheimer's disease. Studies with 11C-nicotine and positron emission tomography
44. 11C]-nicotine in the brains of rhesus monkey. An attempt to study nicotinic receptors in vivo
45. Tacrine restores cholinergic nicotinic receptors and glucose metabolism in Alzheimer patients as visualized by positron emission tomography
46. Imaging of nicotinic and muscarinic receptors in Alzheimer's disease: Effect of tacrine treatment
47. 11C-nicotine binding in normal and Alzheimer brains - In vivo assessment using positron emission tomography
48. Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains
49. In vivo imaging of human cerebral acetylcholinesterase
50. The role of emission tomography in dementia
51. Association between brain functional failure and dementia severity in Alzheimer's disease: Resting versus stimulation PET study
52. 11C]physostigmine
53. In vivo fatty acid incorporation into brain phospholipids in relation to signal transduction and membrane remodeling
54. Neurochemical characteristics of early and late onset types of Alzheimer's disease
55. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
56. 11C]nicotine in rhesus monkeys
57. Neuroimaging and genetic assessment for early diagnosis of Alzheimer's disease
58. Changes in the rCBF images of patients with Alzheimer's disease receiving Donepezil therapy
59. Tacrine interacts with an allosteric activator site on alpha4beta2 nAChRs in M10 cells
60. Cerebral glucose metabolism in presenile dementia of the Alzheimer type - Follow-up of therapy with muscarinergic choline agonists
61. 11C] methyl-tetrahydroaminoacridine distribution and kinetics in healthy human subjects
62. The acetylcholine releaser linopirdine increases parietal regional cerebral blood flow in Alzheimer's disease
63. Imaging nicotinic acetylcholine receptors with fluorine-18-FPH, an epibatidine analog
64. 11C]raclopride in the human brain
65. Visual form of Alzheimer's disease and its response to anticholinesterase therapy
66. Visualization of the vesicular acetylcholine transporter in cholinergic nerve terminals and its targeting to a specific population of small synaptic vesicles
67. 123IQNB and single photon emission computed tomography
68. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease
69. Synthesis and amyloid binding properties of rhenium complexes: Preliminary progress toward a reagent for SPECT imaging in Alzheimer's disease brain
70. 11C]NMPB and positron emission tomography: Method development and differentiation of tracer delivery from receptor binding